神经科

订阅

MedSci主页 / 所有栏目 / 神经科

Neurobiol Aging：降压药哌唑嗪或有助治疗阿尔茨海默病

2012-10-29 MedSci Neurobiol Aging

阿尔茨海默病哌唑嗪降压药老年痴呆
关注

　　    英国的一项新研究显示，一种常用降血压药哌唑嗪可能有助于治疗阿尔茨海默病。患有该病的实验鼠服用这种降压药后，其记忆力减退的症状明显得到缓解。 　　英国帝国理工学院等机构的研究人员在新一期学术刊物《老年神经生物学》上报告说，去甲肾上腺素在记忆等方面具有重要作用，它的作用被扰乱是阿尔茨海默病的表现之一。研究人员因此在大量药物中筛选能调节去甲肾上腺素的物质，结果发现常用

　　

   英国的一项新研究显示，一种常用降血压药哌唑嗪可能有助于治疗阿尔茨海默病。患有该病的实验鼠服用这种降压药后，其记忆力减退的症状明显得到缓解。

　　英国帝国理工学院等机构的研究人员在新一期学术刊物《老年神经生物学》上报告说，去甲肾上腺素在记忆等方面具有重要作用，它的作用被扰乱是阿尔茨海默病的表现之一。研究人员因此在大量药物中筛选能调节去甲肾上腺素的物质，结果发现常用的降血压药哌唑嗪具有这种效果。

　　动物实验显示，如果给患有阿尔茨海默病的实验鼠服用哌唑嗪，可以维持它们的记忆力，这些实验鼠不会像通常患有该病的同类那样记忆力减退。

　　研究人员玛格达莱娜·萨斯特雷说，对于哌唑嗪的上述疗效还需进一步研究，将来有望在此基础上开发出治疗阿尔茨海默病的新方法。

　　阿尔茨海默病又名早老性痴呆症，其病因是大脑中一种淀粉状蛋白出现异常堆积，导致脑细胞受损，记忆力下降，目前尚无有效治疗方法。

链接：
Katsouri L, Vizcaychipi MP, McArthur S, Harrison I, Suárez-Calvet M, Lleo A, Lloyd DG, Ma D, Sastre M.Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease.Neurobiol Aging. 2012 Oct 11. pii: S0197-4580(12)00466-6. doi: 10.1016/j.neurobiolaging.2012.09.010

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2012-11-02 396094184_42047355

    #哌唑嗪#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2013-03-24 ms1948154235210413

    #阿尔茨#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2013-09-06 12498ebem31暂无昵称

    #Biol#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2013-04-05 sunylz

    #Bio#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2013-08-09 12498da4m32(暂无昵称)

    #阿尔茨海#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2012-10-30 经常头晕

    #降压#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2006151, encodeId=e895200615181, content=<a href='/topic/show?id=46993989894' target=_blank style='color:#2F92EE;'>#哌唑嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39898, encryptionId=46993989894, topicName=哌唑嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dca2500075, createdName=396094184_42047355, createdTime=Fri Nov 02 06:00:00 CST 2012, time=2012-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816552, encodeId=3f631816552f3, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Mar 24 21:00:00 CST 2013, time=2013-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766808, encodeId=4ef61e668088f, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Sep 06 00:00:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916928, encodeId=fb481916928ea, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 05 04:00:00 CST 2013, time=2013-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817575, encodeId=1633181e57576, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Aug 09 08:00:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291777, encodeId=38571291e772f, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469929, encodeId=252c146992984, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Oct 30 15:00:00 CST 2012, time=2012-10-30, status=1, ipAttribution=)]
    2012-10-30 yhj-time

    #阿尔茨海默#

    0

相关资讯

抗癌老药蓓萨罗丁进入新的阿尔茨海默病研究

蓓萨罗丁在阿尔茨海默病样病理状态的小鼠体内可清除β淀粉样脑斑块，这种已有十多年应用历史的抗癌药将在9月份开始进行其治疗阿尔茨海默病的首项人体试验。 Gary E. Landreth博士 克利夫兰市凯斯西储大学的Gary E. Landreth博士介绍，这项Ⅰb期试验将随机给予12例健康受试者蓓萨罗丁(Targretin)或安慰剂治疗。研究者将在用药后36 h内每小时收集脑脊液和血液，查看

ADI发布《2012世界阿尔茨海默病》报告

 国际阿尔茨海默病协会 (Alzheimer's Disease International, ADI) 于9月21日发布了最新的《世界阿尔茨海默病》报告，题为“克服痴呆症引发的耻辱感”。报告指出，近四分之一（24%）的痴呆症患者隐瞒或掩盖他们患病的事实，主要因为觉得这是一种耻辱。此外，40%的痴呆症患者称他们被排除在日常活动计划之外。令人吃惊的是，近三分之二的患者及其护理人员认为他们的

Lancet Neurology:银杏叶不能预防阿尔茨海默病

 MedSci评论：  在过去几十年内，不少人认为银杏作为一种古老的树种，它的叶子中含有大量的银杏总黄酮，而黄酮类物质往往具有促进血液循环和抗氧化作用，因此银杏提取物一度用来抗衰老，预防老年性痴呆，是老人追逐的保健品。但是，从临床循证的证据上看，缺乏高等级的循证证据，因此医学界一直对此既不否定也不肯定。而这篇研究，是高等级的循证证据，直接回答了过去的疑问。当然，未来还有必

社会歧视影响阿尔茨海默病照护

    与痴呆和阿尔茨海默病相关的社会歧视给患者本人及其家属都带来了很大的负担，这可能会阻碍疾病的早期诊断和治疗，给社会支持以及家庭或机构照护带来负面影响，甚至可能影响相关研究工作的开展。     世界阿尔茨海默病研究报告（World Alzheimer’s Report）显示，75%的痴呆患者和64%的照护者认为这种负面相关性是存在的

Arch Neurol：ARB类降压药对老年性痴呆（AD）患者有益

患者入选流程图 最近一项尸检研究表明，使用血管紧张素受体拮抗剂（ARB）类的降压药与脑内阿尔茨海默病样病理出现少相关。研究者发现采用CERAD制定的神经病理学标准，生前服用ARB类降压药的AD患者与服用其它降压药的患者相比（37% vs. 54%，P=0.005），病理表现较轻。在校正年龄、性别、APOE分型和血压等变量后，生前服用ARB类降压药的AD患者与服用其它降压的患者尸检AD病理变化的O

2012阿尔茨海默国际高层论坛召开

    10月19日，为期三天的2012年阿尔茨海默国际高层论坛在北京召开。论坛围绕如何维护大脑健康、阿尔茨海默病的基础与临床研究等展开研讨，来自中国、美国、日本等国的50多名专家作了演讲。   据了解，作为世界上人口老龄化速度最快的国家，近年来，中国阿尔茨海默病的发病率在快速增加。目前，我国约有900万名阿尔茨海默病人，且患病人数以每年30万人以上的